Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test
Open Access
- 13 January 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diagnostic Pathology
- Vol. 5 (1), 3
- https://doi.org/10.1186/1746-1596-5-3
Abstract
Carcinomas of unknown primary (CUP) represent approximately 3%-5% of malignant neoplasms. Identifying the tissue of origin (TOO) in these tumors allows for more specific treatment and improves outcomes. However, primary classification remains a challenge in many cases. We evaluated the ability of a microarray-based gene expression test to identify the TOO in tumor specimens from 21 patients with a diagnosis of CUP. The Pathwork® TOO Test was used to measure gene expression patterns for 1550 genes; these were compared for similarity to patterns from 15 known tissue types. The TOO Test yielded a clear single positive call for the primary site in 16 of 21 (76%) specimens and was indeterminate in 5 (24%). The positive results were consistent with clinicopathologic suggestions in 10 of the 16 cases (62%). In the remaining six cases the positive results were considered plausible based on clinical information. Positive calls included colorectal (5), breast (4), ovarian (3), lung (2), and pancreas (2). The TOO Test ruled out an average of 11 primary tissues in each CUP specimen. The Pathwork TOO Test reduced diagnostic uncertainty in all CUP cases and could be a valuable addition or alternative to current diagnostic methods for classifying uncertain primary cancers.Keywords
This publication has 43 references indexed in Scilit:
- Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown PrimaryJournal of Clinical Oncology, 2008
- Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primaryBritish Journal of Cancer, 2008
- Interlaboratory Performance of a Microarray-Based Gene Expression Test to Determine Tissue of Origin in Poorly Differentiated and Undifferentiated CancersThe Journal of Molecular Diagnostics, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary siteCancer, 2007
- Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2007
- Cancer of Unknown Primary Site: Missing Primary or Missing Biology?The Oncologist, 2007
- A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay to Identify Metastatic Carcinoma Tissue of OriginThe Journal of Molecular Diagnostics, 2006
- An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown OriginCancer Research, 2005
- Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network StudyJournal of Clinical Oncology, 2002